
Action Pharma’s sale of a promising candidate drug to Abbott is on the list of the ten biggest biotech deals in Denmark within the last 5 years, and now the US pharmaceutical group’s million-dollar purchased will continue in clinical phases in the hope that the candidate, AP214, will eventually go all the way to approval.
“We will now initiate phase IIb based on the results created in phase IIa. Denmark is a part of this development program, and we look forward to it. And we are hopeful about future results within this area,” says Christina Horan, CEO of the newly-founded Abbott spin-out, Abbvie.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app